Abstract
Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Current Chemical Biology
Title: Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Volume: 3 Issue: 3
Author(s): Ana Maria Inda, Marcela Nilda Garcia, Laura Beatriz Andrini, Adriana Laura Garcia, Ayelen Fernandez Blanco, Cecilia Cristina Furnus, Susana Mercedes Galletti, Javier Brandoni, Jorge Guillermo Martinez, Guillermo Daniel Prat and Ana Lia Errecalde
Affiliation:
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Abstract: Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Export Options
About this article
Cite this article as:
Inda Maria Ana, Garcia Nilda Marcela, Andrini Beatriz Laura, Garcia Laura Adriana, Blanco Fernandez Ayelen, Furnus Cristina Cecilia, Galletti Mercedes Susana, Brandoni Javier, Martinez Guillermo Jorge, Prat Daniel Guillermo and Errecalde Lia Ana, Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer, Current Chemical Biology 2009; 3 (3) . https://dx.doi.org/10.2174/2212796810903030302
DOI https://dx.doi.org/10.2174/2212796810903030302 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Current Status of Vitamin D Signaling and Its Therapeutic Applications
Current Topics in Medicinal Chemistry Established Treatments of Psoriasis
Current Drug Targets - Inflammation & Allergy Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets EDITORIAL (Hot Topic: “Signal Transduction and Response to Anti-Cancer Therapy”)
Current Signal Transduction Therapy Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Current Topics in Medicinal Chemistry Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Detection of Cancer Cells on a Chip
Current Topics in Medicinal Chemistry